Biotechnology
29 December 2025 Edwards v Meril, Teva and the FTC, and modified jury verdicts—lawyers from WilmerHale provide a review of the key cases of the year and their implications.
24 December 2025
3 December 2025
27 November 2025
18 November 2025
Latest Features
Americas
Companies that integrate data rights into their IP strategy with a holistic approach will lead in innovation while minimising risk, says Terri Shieh-Newton of Mintz.
Americas
In the complex world of bsAb patenting, counsel need to turn chefs to serve up success. Benjamin Pelletier of Haynes Boone puts together a menu of dos and don’ts.
Europe
As Big Pharma stalls investment in the UK, the government urgently needs to return to the negotiating table to salvage a key growth area, writes Tim Belcher of EIP.
Americas
In the second of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax delve into the real reasons why medicine costs more in the US.
Americas
In the first of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax explore how legislative, judicial, and executive policies have dramatically altered the risks for drug innovation.
Biotechnology
Erik Viik of Papula-Nevinpat looks at the dynamics that international applicants need to be aware of to secure and manage their patent rights across the region.
Americas
With growing legislation, research and demand for medical use, cannabis presents an economic opportunity for the Caribbean—but IP rights in the region have some way to go, write Keesha Fleming Lake of Keesha Fleming Lake, and Rachael Lodge Corrie of Foga Daley.
Americas
A patent fee structure being mooted in the US could hurt the innovation economy, especially in industries like biotech and pharma—and will face backlash from businesses, writes Paul Hunter of Foley.
More News
11 November 2025 Partnering with AI vendors can open doors for startups and small companies but it also brings serious risks. Experts at AI & IP Europe share key lessons on contracts, data ownership, ring-fencing, monitoring, and exit planning, as Marisa Woutersen reports.
11 November 2025 Cosmetics companies are increasingly using biological molecules in product applications but will need to draft patent applications carefully in this ‘grey area’.
6 November 2025 Womble Bond Dickinson has expanded its West Coast footprint with the addition of a seasoned patent litigator, strengthening the firm’s life sciences capabilities amid rising IP disputes and rapid biotech innovation.
31 October 2025 Rising patent litigation over rare disease treatments highlights the success of the Hatch-Waxman and Orphan Drug Acts, says John Cox at Barnes & Thornburg.
30 October 2025 Danish pharma giant sweetens offer for hot peptide therapeutics company, aiming to cement its market position amid an intensifying GLP-1 patent race.
29 October 2025 With fraudsters exploiting new technologies, the company’s Kenya Williams explains why vigilant enforcement is money well spent to maintain a ‘clean’ brand.
27 October 2025 As IP plays a more important role in corporate valuations, acquirers are discovering that the biggest risks in life sciences deals aren’t always in the patents—they’re in the code, the algorithms, and the data. A panel at LSPN North America Fall shared why traditional due diligence is no longer enough.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox